局部应用CCL22结合的阿巴胺抑制接触过敏
Anna Jonczyk1, Marlene Gottschalk2, Matthew S J Mangan3
1Chemical Biology and Chemical Genetics, Life and Medical Sciences (LIMES) Institute, University of Bonn, 53121 Bonn, Germany.
Molecular therapy. Nucleic acids
|July 29, 2024
概括
研究人员开发了一种DNA吸收体,AJ102.29m,以抑制化学因CCL22,在小鼠模型中有效治疗过敏接触性皮肤炎. 局部应用被证明与系统管理一样有效,这表明了新的治疗可能性.
科学领域:
- 免疫学 免疫学 免疫学
- 皮肤病学 皮肤病学
- 生物技术是生物技术.
背景情况:
- 过敏性接触性皮肤炎是一种常见的职业病,治疗选择很少.
- 化学因子CCL22对免疫细胞迁移至关重要,并与过敏反应有关.
研究的目的:
- 研究CCL22在过敏性接触性皮肤炎中的作用.
- 开发和评估一种用于抑制CCL22的DNA合体,作为潜在的治疗方法.
主要方法:
- 使用SELEX.22生成CCL22特定的DNA吸收体.
- 通过接触过敏小鼠模型,在体外测试了aptamer的有效性,以抑制T细胞迁移,并在体内测试T细胞迁移.
- 评估aptamer透到皮肤组织.
主要成果:
- 在小鼠模型中,CCL22的遗传缺陷改善了过敏反应.
- 在实验室中,AJ102.29m的DNA合酶有力抑制了CCL22依赖的T细胞迁移.
- AJ102.29m有效地减少了系统和局部的过敏接触性皮肤炎症状,穿透了皮肤层.
结论:
- CCL22是过敏性接触性皮肤炎的可行的治疗点.
- DNA 体 AJ102.29m 显示出过敏性接触性皮肤炎的显著治疗潜力.
- 局部的阿普塔默应用为治疗皮肤过敏提供了一个有前途的替代方案.
相关概念视频
02:06Allergic Reactions
Overview
01:30Drug Toxicity: Allergic Reactions
Drug-related allergies are immune-mediated responses triggered by the administration of pharmacological agents. These hypersensitivity reactions are classified based on the immune mechanisms involved. The four primary types—Type I, II, III, and IV—are mediated by different immunological pathways and exhibit distinct clinical manifestations.Type I Hypersensitivity/ IgE-Mediated Reactions: Immunoglobulin E (IgE) immediately mediates Type I hypersensitivity reactions. Upon initial exposure to a...
01:30Allergic Reactions: Anaphylaxis
Anaphylaxis is a severe, life-threatening hypersensitivity reaction mediated by Immunoglobulin E (IgE) antibodies. When IgE binds to allergens, it triggers the release of mediators– histamine, leukotrienes, and prostaglandins from mast cells and basophils. These mediators cause vasodilation, edema, and inflammation, leading to various symptoms.The primary allergens causing anaphylaxis include food items (e.g., peanuts, shellfish), drugs (e.g., penicillin, asparaginase, corticotropin, heparin),...